当前位置: X-MOL 学术Vet. Comp. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Contrast-enhanced ultrasound for sentinel lymph node mapping in the routine staging of canine mast cell tumours: A feasibility study
Veterinary and Comparative Oncology ( IF 2.1 ) Pub Date : 2020-08-24 , DOI: 10.1111/vco.12647
Quentin Fournier 1 , Florence Thierry 1, 2 , Maurizio Longo 1, 3 , Alexandra Malbon 4 , Paola Cazzini 4 , Jocelyn Bisson 1 , Samantha Woods 1, 5 , Tiziana Liuti 1 , Spela Bavcar 1
Affiliation  

Canine mast cell tumours (MCTs) typically spread to lymph nodes (LNs) before reaching distant sites, and LN assessment is an important part of MCT staging. Sentinel LN (SLN) mapping techniques to identify draining LNs are being developed and could improve the accuracy of MCT staging. The primary objective of this feasibility study was to determine the safety and effectiveness of contrast-enhanced ultrasound (CEUS) to identify SLNs. Secondary objectives were to determine if the SLNs identified by CEUS coincided with the regional LN predicted by the anatomical lymphosomes, if previous MCT excision altered CEUS SLN findings, and if CEUS could identify MCT nodal metastases. Between June 2017 and March 2019, 59 dogs with 62 MCTs were enrolled. No adverse events related to CEUS were reported. CEUS detected at least 1 SLN in 59/62 MCTs (95.2%, 95% CI: 86.5-99.0%). In only 32/59 (54.2%) MCTs, clinicians would have correctly predicted the SLN(s) identified by CEUS. Among the 35 MCTs that had histological examination of the SLN(s), the prevalence of metastasis was 60% (95% CI: 42.1-76.1%). Additional staging procedures did not reveal any metastases in dogs with histologically non-metastatic SLNs. Integration of CEUS SLN mapping into the routine staging of MCTs is promising, but future studies are required to refine this procedure and to investigate if it would translate into a clinical benefit.

中文翻译:

犬肥大细胞瘤常规分期前哨淋巴结标测的增强超声:可行性研究

犬肥大细胞瘤 (MCT) 通常在到达远处之前扩散到淋巴结 (LN),而 LN 评估是 MCT 分期的重要组成部分。用于识别引流 LN 的前哨 LN (SLN) 映射技术正在开发中,可以提高 MCT 分期的准确性。这项可行性研究的主要目的是确定对比增强超声 (CEUS) 识别 SLN 的安全性和有效性。次要目标是确定 CEUS 识别的 SLN 是否与解剖淋巴体预测的区域 LN 一致,之前的 MCT 切除是否改变了 CEUS SLN 的发现,以及 CEUS 是否可以识别 MCT 淋巴结转移。在 2017 年 6 月至 2019 年 3 月期间,共有 59 只狗与 62 个 MCT 被招募。没有报告与 CEUS 相关的不良事件。CEUS 在 59/62 MCT 中检测到至少 1 个 SLN(95.2%,95% CI:86。5-99.0%)。仅在 32/59 (54.2%) 个 MCT 中,临床医生会正确预测 CEUS 识别的 SLN。在对 SLN 进行组织学检查的 35 个 MCT 中,转移的发生率为 60%(95% CI:42.1-76.1%)。额外的分期程序未显示具有组织学非转移性 SLN 的狗的任何转移。将 CEUS SLN 映射整合到 MCT 的常规分期中是有希望的,但需要未来的研究来完善这一程序并调查它是否会转化为临床益处。额外的分期程序未显示具有组织学非转移性 SLN 的狗的任何转移。将 CEUS SLN 映射整合到 MCT 的常规分期中是有希望的,但需要未来的研究来完善这一程序并调查它是否会转化为临床益处。额外的分期程序未显示具有组织学非转移性 SLN 的狗的任何转移。将 CEUS SLN 映射整合到 MCT 的常规分期中是有希望的,但需要未来的研究来完善这一程序并调查它是否会转化为临床益处。
更新日期:2020-08-24
down
wechat
bug